Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Aplaviroc. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 known ✓ | P51681 | 20/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 3/20 | 1.00 |
| ▸ | CXCR4 | P61073 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.87 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aplaviroc SCHEMBL5578746 | 1.00 | CCR5 (1.00) | CCR5CYP2C9CXCR4CYP2D6 | |
| Aplaviroc SCHEMBL5578734 | 1.00 | CCR5 (1.00) | CCR5CYP2C9CXCR4CYP2D6 | |
| Aplaviroc SCHEMBL5346716 | 1.00 | CCR5 (1.00) | CCR5CYP2C9CXCR4CYP2D6 | |
| Aplaviroc SCHEMBL6190417 | 1.00 | CCR5 (1.00) | CCR5CYP2C9CXCR4CYP2D6 | |
| Aplaviroc SCHEMBL5578741 | 1.00 | CCR5 (1.00) | CCR5CYP2C9CXCR4CYP2D6 | |
| Aplaviroc SCHEMBL6186135 | 1.00 | CCR5 (1.00) | CCR5CYP2C9CXCR4CYP2D6 | |
| Hydrochloric Acid SCHEMBL6186236 | 1.00 | CCR5 (1.00) | CCR5CYP2C9CXCR4CYP2D6 | |
| Aplaviroc SCHEMBL15531476 | 0.99 | CCR5 (1.00) | CCR5CYP2C9CXCR4CYP2D6 | |
| Hydrochloric Acid SCHEMBL5343787 | 0.99 | CCR5 (1.00) | CCR5CYP2C9CXCR4CYP2D6 | |
| Aplaviroc SCHEMBL4577106 | 0.99 | CCR5 (1.00) | CCR5CYP2C9CXCR4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260108561-A1 | COMPOSITION FOR CELL TRANSPLANTATION THERAPY AND THE USE THEREOF | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2026-04-23 | — | — | US | claimed |
| EP-4598598-A1 | COMPOSITION FOR CELL TRANSPLANTATION THERAPY AND THE USE THEREOF | National University of Singapore (SG) | 2025-08-13 | — | — | EP | claimed |
| WO-2024076303-A1 | COMPOSITION FOR CELL TRANSPLANTATION THERAPY AND THE USE THEREOF | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2024-04-11 | — | — | WO | claimed |
| US-7361758-B2 | Crystals of triazaspiro[5.5]undecane derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-04-22 | — | — | US | claimed |
| EP-1378510-B1 | TRIAZASPIRO (5.5) UNDECANE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2006-06-07 | — | — | EP | claimed |
| US-7053090-B2 | Triazaspiro[5.5]undecane derivatives and drugs containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-05-30 | — | — | US | claimed |
| US-20060052407-A1 | Novel crystals of triazaspiro [5.5] undecane derivative | ONO PHARMACEUTICAL CO,., LTD (JP) | 2006-03-09 | — | — | US | claimed |
| EP-1541573-A1 | NOVEL CRYSTALS OF TRIAZASPIRO 5.5 UNDECANE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-06-15 | — | — | EP | claimed |
| US-20260108561-A1 | COMPOSITION FOR CELL TRANSPLANTATION THERAPY AND THE USE THEREOF | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2026-04-23 | — | — | US | disclosed |
| EP-4598598-A1 | COMPOSITION FOR CELL TRANSPLANTATION THERAPY AND THE USE THEREOF | National University of Singapore (SG) | 2025-08-13 | — | — | EP | disclosed |
| US-20250213601-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | Didenko, Kirill (US) | 2025-07-03 | — | — | US | disclosed |
| EP-3782649-B1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2025-05-14 | — | — | EP | disclosed |
| WO-2024076303-A1 | COMPOSITION FOR CELL TRANSPLANTATION THERAPY AND THE USE THEREOF | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2024-04-11 | — | — | WO | disclosed |
| EP-3528791-B1 | DISPERSIBLE COMPOSITIONS | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2023-12-06 | — | — | EP | disclosed |
| EP-1410031-A2 | METHODS OF PREPARING MULTICOLOR QUANTUM DOT TAGGED BEADS AND CONJUGATES THEREOF | ADVANCED RESEARCH AND TECHNOLOGY INSTITUTE, Inc. (US) | 2004-04-21 | — | — | EP | disclosed |
| WO-2004026874-A1 | NOVEL CRYSTALS OF TRIAZASPIRO[5.5]UNDECANE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-04-01 | — | — | WO | disclosed |
| EP-1378509-A1 | DRUGS CONTAINING TRIAZASPIRO 5.5]UNDECANE DERIVATIVES AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-01-07 | — | — | EP | disclosed |
| EP-1378510-A1 | TRIAZASPIRO 5.5]UNDECANE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-01-07 | — | — | EP | disclosed |
| US-20030148544-A1 | Methods of preparing multicolor quantum dot tagged beads and conjugates thereof | ADVANCED RESEARCH AND TECHNOLOGY INSTITUTE, INC. | 2003-08-07 | — | — | US | disclosed |
| WO-2003003015-A2 | METHODS OF PREPARING MULTICOLOR QUANTUM DOT TAGGED BEADS AND CONJUGATES THEREOF | ADVANCED RESEARCH AND TECHNOLOGY INSTITUTE, INC. (US) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052407-A1 | Novel crystals of triazaspiro [5.5] undecane derivative | ACKR3, CCR10, CCR9 | CCR5 4/4885CYP2C9 836/4885CXCR4 19/4885 |
| US-20260108561-A1 | COMPOSITION FOR CELL TRANSPLANTATION THERAPY AND THE USE THEREOF | CCR5, CCRL2, CXCL12 | CCR5 1/4885CYP2C9 4656/4885CXCR4 21/4885 |
| US-20250213601-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | ACE2, FURIN, SARS1 | CCR5 333/4885CYP2C9 56/4885CXCR4 428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.